Angiotensin II in COVID-19 [COVID-19]
Research type
Research Study
Full title
Efficacy and Safety of Angiotensin II use in COVID-19 Patients with Acute Respiratory Distress Syndrome
IRAS ID
283005
Contact name
Marlies Ostermann
Contact email
Sponsor organisation
Guy's & St Thomas' NHS Foundation Hospital
Duration of Study in the UK
1 years, 0 months, 1 days
Research summary
This study aims to find out whether the use of angiotensin II, which is a drug to raise blood pressure has been approved by European Medical Agency in August 2019, as an add-on medication to increase blood pressure in patients with COVID-19, acute severe lung injury, inflammation and severe shock, compared with standard medication. In addition, we will collect the data of Anakinra, another drug which is frequently used in this condition to reduce inflammation. \nWe will collect clinical data and outcomes from critical care patients. We will analyse for whom these drugs are most beneficial and explore whether there are any patients who don’t benefit or have side effects.
REC name
East of England - Cambridge Central Research Ethics Committee
REC reference
20/EE/0143
Date of REC Opinion
26 May 2020
REC opinion
Favourable Opinion